Shares of VolitionRx Limited (NYSEAMERICAN:VNRX – Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.00 and traded as high as $0.76. VolitionRx shares last traded at $0.73, with a volume of 44,624 shares trading hands.
VolitionRx Price Performance
The firm has a market cap of $46.12 million, a P/E ratio of -1.30 and a beta of 1.59.
VolitionRx (NYSEAMERICAN:VNRX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. VolitionRx had a negative return on equity of 15,493.47% and a negative net margin of 9,158.31%. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. Sell-side analysts predict that VolitionRx Limited will post -0.5 EPS for the current fiscal year.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Recommended Stories
- Five stocks we like better than VolitionRx
- The 3 Best Fintech Stocks to Buy Now
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Plot Fibonacci Price Inflection Levels
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- ETF Screener: Uses and Step-by-Step Guide
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.